

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

Uveitis is a group of intraocular inflammatory disorders affecting the middle layer of the eye (the uvea) which can cause significant visual impairment, causing partial or complete loss of vision. Non-infectious uveitis may be due to an underlying inflammatory condition, an autoimmune disorder or as a result of trauma to the eye. In many cases the cause remains uncertain. It is estimated that only 10 in 100,000 adults and 3 in 100,000 children are diagnosed with noninfectious posterior uveitis (Thorne et al. 2016). The goals of therapy in noninfectious posterior uveitis is to eliminate intraocular inflammation, relieve discomfort, prevent visually significant complications, minimize recurrences, and prevent the occurrence of sight-threatening complications secondary to the disease or the therapy itself. The mainstay of treatment of intermediate and posterior uveitis is systemic or local corticosteroids. Posterior uveitis is challenging to treat and often unresponsive to topical administration of steroids due to inadequate therapeutic drug penetration to the posterior ocular tissues. (Tan et al. 2016). Long-term systemic steroid therapy, although highly effective, is associated with various serious adverse effects and intolerance. Immunosuppressive drugs and biological agents such as tumor necrosis factor inhibitors may be used as 'steroid sparing' treatments; however, most of these treatments also are present adverse effect profiles. While topical corticosteroids administered as eye drops are generally better tolerated than systemic corticosteroids, it is generally more effective for anterior uveitis than with posterior uveitis. Side effects of local ophthalmic corticosteroids include a high rate of cataract and complications due to increased intraocular pressure (IOP). Other forms of local therapy for corticosteroid include local injection (sub-Tenon's or intravitreal) and intraocular drug implants [i.e., dexamethasone intravitreal implant (Ozurdex), fluocinolone acetonide intravitreal implant (Retisert, Iluvien)].

Diabetic macular edema (DME) is macular thickening secondary to DR that may be present in any of the stages of this disease. DME can be present in all stages of DR and is the most common cause of vision loss in patients with DR with an increasing prevalence tied to type 2 diabetes mellitus. Inflammation plays an important role in the pathogenesis of DME. The breakdown of the blood–retinal barrier involves the expression of inflammatory cytokines and growth factors, including vascular endothelial growth factor (VEGF). Although the exact mechanism of corticosteroid on ocular tissues is not fully understood, steroids have demonstrated efficacy in the treatment of DME by inhibiting many of the processes known to be involved in the progression of DME, through anti-inflammatory properties and VEGF inhibition. Visual acuity and macular thickness are two central parameters in the follow-up of patients with DME. Three synthetic corticosteroids (dexamethasone, fluocinolone, and triamcinolone) have been used mainly in the treatment of DME. Corticosteroids have a broad spectrum of biologic action and noted to inhibit some of the processes known to be involved in the progression of DME through anti-inflammatory properties and VEGF inhibition which results in anti-vascular permeability and antiangiogenic effects and stabilizes retinal capillaries (Daruich et al. 2018). Ozurdex (dexamethasone intravitreal implant) is the first intravitreally injectable drug implant approved for the treatment of DME.

Other treatment options for DME include intravitreal anti-VEGF and photocoagulation (laser therapy). Macular laser photocoagulation is effective in preserving vision by slowing the progression of retinopathy and reducing visual loss but has a limited effect in restoring lost vision. Although first-line treatment of DME with anti-VEGF agents, with or without laser, have become the standard treatment for DME, there is no consensus on the treatment of patients who do not respond, or are contraindicated to anti-VEGF agents. Focal photocoagulation is an established treatment for DME and can be used as initial therapy in poorly compliant patients with DME, who may not return for follow-up

appointments, or as adjunctive therapy for patients who do not respond or have an incomplete response to anti-VEGF therapy (UTD 2021). The efficacy of intravitreal injection of anti-VEGF has been proven in several RCTs, which reported better outcomes compared to macular laser photocoagulation in DME (Blinder et al. 2017; Lazic et al. 2014).

Retinal vein occlusion (RVO) is a blockage of a portion of the venous circulation that drains the retina and is classified according to where the occlusion is located. Pressure builds up in the capillaries and result in hemorrhage and leakage of fluid and blood which can lead to macular edema with leakage near the macula. Central retinal vein occlusion (CRVO) occurs when the blockage is in the main vein in the retina. Branch retinal vein occlusion (BRVO) occurs when the blockage is one of the smaller veins attached to the main vein in the retina. The prognosis of RVOs varies according to the site of the occlusion and the type of occlusion (ischemic or nonischemic). In general, more-distal RVOs with less occlusion have a better prognosis than more-proximal RVOs with greater ischemia. VEGF increases vessel permeability by increasing the phosphorylation of tight junction proteins and thus an important mediator of the blood-retinal barrier breakdown leading to vascular leakage and macular edema (EURETINA 2019). Therefore, therapy that inhibits VEGF is an effective therapeutic modality targeting the underlying pathogenesis of macular edema. Pharmacologic treatment with intravitreal anti-VEGF agents is first-line therapy for macular edema (Fraser, C et al. 2021). Intravitreal glucocorticoid therapy is considered an alternative for patients with edema refractory to anti-VEGF monotherapy. Corticosteroids inhibit the expression of VEGF, a cytokine that is expressed at increased concentrations in macular edema and is a potent promoter of vascular permeability.

Ozurdex is the first FDA-approved treatment for macular edema secondary to BRVO and CRVO. Ozurdex is a sustained-release intravitreal implant of 0.7mg dexamethasone designed to release over a 6-month period. Dexamethasone is combined with biodegradable material in the form of a small rod, which is injected into the vitreous cavity using a customized, single-use, 22-gauge applicator. Dexamethasone is released in a biphasic manner over 6 months, with higher concentrations released for the first 6 weeks, followed by lower concentrations for the following months. After this time, the implant dissolves to CO₂ and H₂O leaving no residue within the eye. The mean number of Ozurdex injections reported in the literature is 4.2 injections per year, and more than 6 consecutive injections have been reported (Haller et al. 2010, 2011). Ozurdex is indicated for the treatment of DME, macular edema associated with RVO, and non-infectious posterior uveitis. Dexamethasone intravitreal implant (Ozurdex) received FDA approval based on MEAD trial results, in which administration was every 6 months and injections mean number over 3 years was 4.1 (Boyer et al. 2014).

For patient intolerant or refractory to other therapies, or likely to experience severe adverse events from systemic corticosteroids, an intravitreal implant delivering sustained-release corticosteroid is a therapeutic option. The continuous local release of steroid with an implant may reduce or eliminate long-term systemic therapy or frequent intravitreal injections; however, it should be noted that insertion or surgical implantation of the device also carries risks such as endophthalmitis, ocular inflammation, and retinal detachments. Furthermore, prolonged use of ophthalmic dexamethasone includes increased IOP, glaucoma with possible damage to the optic nerve, defects in visual acuity and visual field, posterior subcapsular cataract formation, secondary ocular infection from pathogens (including herpes simplex), and perforation of the globe where there is thinning of the cornea or sclera. Cataracts are a frequent complication of long-term corticosteroid therapy and should be considered regardless of the route of administration.

COVERAGE POLICY

Ozurdex (dexamethasone intravitreal implant) for treatment of patients with non-infectious uveitis, macular edema following retinal vein occlusion, and DME **may be considered medically necessary** when **ALL** of the following clinical criteria are met:

1. Definitive diagnosis of **ONE** of the following:

a. DME; **OR**

Informational Note: DME is indicated by the presence of clinically significant macular edema as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS): Retinal thickening within 500 micrometers (µm) of the center of the fovea, OR Hard exudates within 500 µm (≤ 500 micrometers) of the fovea center with adjacent retinal thickening, OR At least 1 disc area of retinal thickening, any part of which is within 1 disc diameter of the center of the fovea

b. Macular Edema due to BRVO or CRVO; **OR**

c. Chronic (duration of 1 year or more) Non-infectious *Posterior Segment Uveitis*.

NOTE: Ozurdex is not for use in *anterior* uveitis or in uveitis caused by infection.

Molina Clinical Policy

Ozurdex (dexamethasone intravitreal implant): Policy No. 282

Last Approval: 6/8/2022

Next Review Due By: June 2023



AND

2. Diagnosis and disease progression (history of progressive visual loss or worsening of anatomic appearance) as confirmed/determined by fluorescein angiography, Optical Coherence Tomography (OCT) or Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

MOLINA REVIEWER: Baseline labs (prior to treatment with requested implant) should be noted in member's profile to reference for review if reauthorization of treatment is requested

AND

3. Vision impairment (sight-threatening or sight-losing) caused by condition. Documentation required.

AND

4. Inadequate response, intolerance, contraindication, or clinical rationale supporting the inappropriateness of the following therapies as applicable to member's specific diagnosis (**a or b or c**). Documentation of ALL therapy with dates of failed therapy or clinical events required.

a. DME

- i. ONE of the following VEGF inhibitors: bevacizumab (Avastin): PREFERRED/NO PA REQUIRED; aflibercept (Eylea), brolucizumab (Beovu); pegaptanib (Macugen), ranibizumab (Lucentis); **AND**
- ii. Laser Photocoagulation

Informational Note: Focal photocoagulation is an established treatment for DME Fraser, CE; UTD 2021

OR

b. Macular Edema due to BRVO and CRVO

- i. ONE of the following VEGF inhibitors: bevacizumab (Avastin): PREFERRED/NO PA REQUIRED; aflibercept (Eylea), brolucizumab (Beovu); pegaptanib (Macugen), ranibizumab (Lucentis); **AND**
- ii. FOR CRVO ONLY (BRVO not required): Intravitreal glucocorticoids (e.g., Triamcinolone acetonide, intravitreal injection)

Informational Note: Randomized trials and cohort studies have found that intravitreal glucocorticoid injections may improve visual acuity in patients with BRVO (SCORE-BRVO) and with CRVO (SCORE-CRVO). The SCORE-CRVO trial suggests that patients with visual acuity loss from macular edema secondary to CRVO may benefit, relative to observation alone, from treatment with 1 mg of preservative-free triamcinolone at baseline and at four-month intervals as needed for one year.

OR

c. Non-infectious Posterior Segment Uveitis

- i. Systemic corticosteroid OR periocular or intravitreal corticosteroid therapy (e.g., Triamcinolone acetonide), **AND**
- ii. Non-Biologic Immunosuppressive Therapy [Antimetabolites (e.g., azathioprine, mycophenolate mofetil (CellCept; Myfortic), or methotrexate) OR Calcineurin inhibitors (e.g., cyclosporine or tacrolimus)]

AND

3. Member was previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure; **AND**
4. Documentation/attestation required for **ALL** of the following:
 - a. Member has been informed about the potential adverse effects of a corticosteroid intravitreal implant, including cataracts, increased intraocular pressure, or hypotony, endophthalmitis, and risk of need for additional surgical procedures.

AND

- b. Requested dexamethasone intravitreal implant (Ozurdex) is NOT intended for administration with other intravitreal implants (e.g., fluocinolone acetonide intravitreal implant [Iluvien/Retisert])

MOLINA REVIEWER: Verify medical/pharmacy claims data and medical history/chart notes for concurrent intravitreal implants

CONTINUATION OF THERAPY

1. Reauthorization request is for the same eye as initial authorization

NOTE: The continuation of therapy criteria is for the same treated eye in which authorization was obtained. If member has developed condition in an untreated eye, Prescriber must submit new request according to the 'Initial Coverage' criteria.

AND

2. Member's continued need for Ozurdex and response to treatment as determined by fluorescein angiography, OCT or SCODI (including disease progression or history of progressive visual loss or worsening of anatomic appearance) has been formally assessed and documentation submitted for review.

NOTE: Ozurdex treatment should be discontinued (and patient monitored) in absence of macular edema or stable visual acuity. Treatment (and monitoring intervals) may be resumed at prescribing specialist's discretion and submission of authorization request with presence of macular edema or visual acuity is decreasing at any time.

NOTE: Retreatment is usually not necessary for patients that have maintained vision improvement. Exceptions may be reviewed on a case-by-case basis with relevant, supporting documentation from Prescriber.

AND

3. **ONE** of the following is applicable based on member's diagnosis:
 - a. DME: Member had an initial positive, but subsequently has experienced decreased vision and/or an increase in retinal thickness, secondary to recurrent or worsening DME; **OR**
 - b. Macular Edema due to CRVO or BRVO: Member experienced an initial positive response to treatment, but has subsequently experienced a loss in visual acuity; **OR**
 - c. Non-infectious Posterior Segment Uveitis: Member experienced an initial positive response to treatment defined as the following, but has subsequently experienced a loss in visual acuity:
 - o Greater than (>) 15 letters (3 lines) in BCVA from baseline after 12 weeks following administration or the patient achieves driving visual acuity; **OR**
 - o Visual acuity is maintained to at least 50% of the best recorded following diagnosis of uveitis

AND

4. Member is likely to benefit from re-treatment without being exposed to significant risk, according to Prescriber's clinical judgment; **AND**
5. Member does not have **ANY** of the following conditions which warrants discontinuation of therapy:
 - a. Loss of visual acuity from baseline (pre-treatment with Ozurdex); **OR**
 - b. Moderately or severely raised IOP in the treated eye is related to Ozurdex **OR**
 - c. Limited clinically meaningful benefit of treatment (e.g., maximal gain in visual acuity is less than five letters on a standard sight chart in the presence of limited anti-inflammatory effect); **OR**
 - d. Absence of macular edema or stable visual acuity.

NOTE: If absence of macular edema or stable visual acuity, Ozurdex treatment should be discontinued, and patient monitored. Treatment and monitoring intervals may be resumed at prescribing specialist's discretion and submission of authorization request if there is presence of macular edema or visual acuity is decreasing at any time.

LIMITATIONS AND EXCLUSIONS

The following are considered **contraindications/exclusions** based on insufficient evidence:

1. Hypersensitivity to dexamethasone or any component of the formulation.
2. Active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, or fungal infections of the eye.

Informational Note: Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
3. Advanced glaucoma: Glaucoma with cup to disc ratios of greater than 0.8.
4. Aphakic eyes with rupture of the posterior lens capsule.
5. Anterior Chamber Intraocular Lens (ACIOL) and Rupture of the Posterior Lens Capsule.

Informational Note: Contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for use.
6. Concurrent treatment with other intravitreal implants (i.e., Fluocinolone acetonide intravitreal implant [Iluvien and Retisert]).

The following are considered **discontinuation** conditions based on insufficient evidence of clinical benefit:

1. Loss of visual acuity from baseline (pre-treatment with Ozurdex); **OR**
2. Moderately or severely raised IOP in the treated eye is related to Ozurdex **OR**
3. Limited clinically meaningful benefit of treatment (e.g., maximal gain in visual acuity is less than five letters on a standard sight chart in the presence of limited anti-inflammatory effect); **OR**
4. Absence of macular edema or stable visual acuity.

NOTE: If absence of macular edema or stable visual acuity, Ozurdex treatment should be discontinued, and patient monitored. Treatment and monitoring intervals may be resumed at prescribing specialist's discretion and submission of authorization request if there is presence of macular edema or visual acuity is decreasing at any time.

The following are considered **experimental, investigational and unproven** based on insufficient evidence:

1. Any indications other than those listed above
2. Combined cataract surgery with intravitreal dexamethasone implant (Ozurdex)
Informational Note: Combined cataract surgery and Ozurdex is considered experimental/investigational for the treatment of cataract and macular edema (ME) due to insufficient evidence of effectiveness of this approach. The safety and effectiveness of intravitreal dexamethasone implant in patients with cataract and ME undergoing phacoemulsification and intra-ocular lens (IOL) implantation was evaluated (Sze et al 2015). A total of 24 eyes with ME secondary to DME and RVO were retrospectively reviewed. These eyes underwent phacoemulsification with IOL implantation and intravitreal dexamethasone implant 0.7 mg at the same setting between September 2012 and September 2013. The authors of the study concluded that combined cataract surgery with intravitreal dexamethasone implant appeared to be safe and effective in treating patients with cataract and ME in this small case series. Furthermore, a larger prospective study with longer follow-up is required to demonstrate the long-term benefit of this combined procedure.
3. Coats' disease
4. Macular edema secondary to idiopathic retinal vasculitis, Aneurysms, Neuroretinitis (IRVAN) syndrome, or retinitis Pigmentosa
5. Non-arteritic anterior ischemic optic neuropathy
6. Proliferative vitreoretinopathy
7. Pseudophakic macular edema (Irvine-Gass syndrome) except for Pseudophakic persons with DME
8. Radiation maculopathy
9. Age-Related Macular Degeneration

Informational Note: The ERIE Study Group published a single-masked, sham-controlled, multicenter trial on the use of a dexamethasone intravitreal implant as adjunctive therapy to treat age-related macular edema (Kuppermann et al. 2015). All patients (n=243) in this study received 2 ranibizumab injections, with the next injection given as needed based on established study criteria. The primary efficacy end point was the ranibizumab injection-free interval. Ozurdex increased the injection interval based on Kaplan-Meier survival analysis. A small, but statistically significant percentage of patients did not require rescue ranibizumab over the 6-month study period (8.3% vs 2.5%). There was a very small reduction in the mean number of as needed ranibizumab injections over the 6 months of the study (3.15 vs. 3.37), but patients in the Ozurdex group received an additional injection of the implant. There were no significant differences between the groups in mean change from baseline BCVA. More patients in the Ozurdex group had increased IOP (13.2% vs 4.2%), however no differences between the groups in cataract-related events.

DURATION OF APPROVAL: 12 months

PRESCRIBER REQUIREMENTS: Prescribed by board-certified ophthalmologists or retinal specialist experienced in the administration of intravitreal injections. Treatment and monitoring must be retained by the specialist. Submit consultation notes if applicable.

AGE RESTRICTIONS: 18 years of age or older

DOSING CONSIDERATIONS

Macular Edema, Noninfectious Uveitis, DME

Adults: 0.7 mg (700 µg) intravitreal implant injected intravitreally in affected eye

QUANTITY LIMITATIONS

ONE dexamethasone intravitreal implant per affected eye every 4 to 6 months

Informational Note: There is limited information on repeat dosing intervals less than 6 months; an interval of approximately 6 months should be allowed between the two injections.

ADMINISTRATION

1. Ozurdex implantation is considered a provider-administered procedure performed under local anesthesia by an ophthalmologist experienced in intravitreal injections (Allergan 2018); **AND**
2. Documentation of the following information required for review and submission of requests. Prescriber to maintain record of administration of intravitreal therapy (recorded in the procedure or post-procedure note following the completion of treatments): Name of the intravitreal therapy; Dose and frequency; Treated eye: right eye, left eye, or both eyes; **AND**
3. If member meets all criteria and approval for therapy is granted, medication will be dispensed by a specialty pharmacy vendor at the discretion of Molina Healthcare; **AND**
4. Refer to MHI Policy & Procedure (P&P): Specialty Medication Administration Site of Care Policy: MHI Pharm 11

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DRUG INFORMATION

ROUTE OF ADMINISTRATION: Intravitreal implant

DRUG CLASS: Anti-inflammatory Agent, Corticosteroid, Ophthalmic

FDA-APPROVED USES:

Macular Edema: Treatment of macular edema following BRVO or CRVO

Non-infectious uveitis: Treatment of non-infectious uveitis affecting the posterior segment of the eye

DME: Treatment of DME

COMPENDIAL APPROVED OFF-LABELED USES: None

SUMMARY OF MEDICAL EVIDENCE**Dexamethasone Implant for DME**

The MEAD (Macular Edema: Assessment of Implantable Dexamethasone in Diabetes) study consists of two multicenter, three-year, sham-controlled, masked RCTs that assess the proportion of patients whose BCVA improved by 15 or more letters from baseline. A total of 1,048 DME patients were enrolled in the study, with 351 receiving a 0.7-mg implant, 347 receiving a 0.35-mg implant, and 348 receiving sham treatment (350 patients). Patients having a BCVA of 34 to 68 ETDRS letters and a central subfield retinal thickness of 300 μ m on OCT were randomly assigned to therapy with dexamethasone implant 0.7 mg, dexamethasone implant 0.35 mg, or a placebo operation in a 1:1:1 ratio. Re-treatment was limited to once every six months for patients who met the re-treatment eligibility criteria. The primary endpoint in the intent-to-treat population with last-observation-carried-forward for missing values was a 15-letter improvement in BCVA from baseline at trial end. Adverse occurrences and IOP were both used as safety measures. More patients treated with dexamethasone implant 0.7-mg experienced a statistically significant improvement in BCVA (22.4 %) compared to patients in the placebo group (12.0 %), as well as a statistically significant reduction in central macular thickness (112 vs. 42 μ m) when compared to patients in the placebo group. Dexamethasone implant 0.7 mg and dexamethasone implant 0.35 mg had a greater mean average reduction in central retinal thickness from baseline during the study than placebo. The dexamethasone intravitreal implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA and reduction in central subfield retinal thickness with an average of 4 to 5 injections over 3 years. (NCT00168337 and NCT00168389 at ClinicalTrials.gov).

Dexamethasone Implant for Noninfectious Posterior Uveitis

The HURON study established the efficacy and safety of dexamethasone intravitreal implants (Ozurdex) in the treatment of noninfectious uveitis affecting the posterior segment (Lowder et al. 2011). The study was a 26-week, multicenter, masked, randomized, sham-controlled trial of a dexamethasone intravitreal implant (n=229). Patients were randomized to 0.35-mg implants (n=76), 0.7-mg implants (n=77), or placebo procedure (n=76) and followed up for 8 weeks with an 18-week masked extension, for a total of 26 weeks. The primary outcome measure of the proportion of eyes with a vitreous haze score of 0 (0 = no inflammation) at week 8 and additional outcome measures were vitreous haze through week 26, BCVA, adverse events, IOP, and biomicroscopy/ophthalmoscopy. The results of the trial indicated that a single dexamethasone intravitreal implant was significantly more effective than placebo at eliminating vitreous haze. At the primary endpoint of week 8, approximately 4 times more eyes treated with the dexamethasone implant 0.7 mg had complete resolution of vitreous haze compared with sham; a total of 47% of patients treated with the 0.7 mg implant achieved the primary outcome measure (a vitreous haze score of 0 at 8 weeks) compared to 10% who received sham control. The incidences of elevated IOP (≥ 25 mm Hg) in phakic eyes were higher in 0.7-mg implant-treated eyes (7.1%) versus sham control eyes (4.2%). Over 26 weeks, 23% or less (n=77) of Ozurdex-treated patients required IOP-lowering medications, and 7.9% (n=76) of patients overall developed a pressure spike greater than or equal to 35 mm Hg. Cataract was observed in 15% of the phakic eyes treated with the implant compared with 7% of eyes in the control group, and only one eye required surgery; however, this difference was not statistically significant. Treatment with the dexamethasone intravitreal implant also led to a significant improvement in BCVA by week 3 that persisted through week 26. Limitations of this study include a shorter follow-up period (6 months), and adverse effects such as cataract formation would not have been detected fully. The long-term efficacy and safety data for the dexamethasone 0.7-mg implant is not available and the trial had no information regarding the efficacy of repeated implantation of 0.7 mg dexamethasone.

Dexamethasone Implant for RVO

Two randomized, prospective, masked, sham-controlled studies evaluated the safety and efficacy of dexamethasone implant (0.7 mg and 0.35 mg to a sham procedure) over an initial 6-month period followed by a 6-month open-label extension (Haller et al. 2010, 2011; Ozurdex GENEVA Study Group). The study enrolled adult patients with macular edema secondary to BRVO or CRVO. Duration of macular edema between 6 weeks and 12 months for BRVO and 6 weeks to 9 months for CRVO was required for inclusion (Haller et al. 2010). The dexamethasone implant 0.7 mg and 0.35 mg were superior to sham procedure in reducing central retinal thickness and improving BCVS through 3 months after administration of a single implant. The proportion of eyes achieving an improvement of at least 15 letters of vision was greater in the treatment groups at month 1 and month 3. However, at month 6 this effect was no longer statistically significant. The reduction in mean OCT central retinal thickness was greater in the 0.7mg and 0.35mg groups than in the sham group at month 3, but not statistically significant at month 6. The dexamethasone intravitreal implant 0.7mg was FDA approved for treatment of patients with RVO-associated macular edema based on the GENEVA study results. In the open-label extension, the adverse events rate was similar between patients who received their first or second DEX implant, except for cataract (Haller et al. 2011). IOP increase in the groups treated with DEX implant was also noticed, which were usually transient and controlled with medications or observation. Also, 30% and 32% of the patients achieved an increase in 15 letters 60 days after the first and second DEX implant, respectively.

Comparative Studies

The BEVORDEX study was the first head-to-head RCT of bevacizumab versus a slow-release intravitreal dexamethasone implant (Ozurdex) for DME (Fraser-Bell et al.). At 12 months, there was no difference between the groups in proportion of eyes achieving the primary endpoint of a 10-letter gain in visual acuity. There was significantly greater decrease in central macular thickness with fewer intravitreal injections in the dexamethasone implant compared with the bevacizumab group at 12 months. However, a greater number of eyes in the dexamethasone implant group lost vision, primarily due to cataract. Similarly, the 24-month results of the BEVORDEX study identified no significant difference in the proportion of eyes with a 10-letter gain in visual acuity between bevacizumab and dexamethasone implant treatment, with both agents providing good improvements (Fraser-Bell et al.). The burden of injections was significantly greater with bevacizumab (mean 9.1 vs. 2.8). However, the dexamethasone implant group had more cases of visual loss, mainly in eyes that were phakic at baseline. Elevated IOP in the dexamethasone implant group could largely be managed with topical therapy. Therefore, the dexamethasone implant could potentially be considered a first-line treatment option in pseudophakic patients and a second-line treatment option in phakic patients with DME.

Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for DME Refractory to Anti-VEGF

A meta-analysis assessed the effect on BCVA and efficacy of 0.7 mg dexamethasone implant (Ozurdex) in 3,859 patients with refractory DME (Khan et al. 2017). Studies included adults undergoing treatment with Ozurdex for DME. At total of 15 studies were included in the final analysis. At a mean follow-up period of 6 months, dexamethasone intravitreal implant treatment in patients with DME refractory to anti-VEGF therapy is associated with a mean improvement of 20 ETDRS letters or a gain of 4 lines. The authors concluded that treatment with Ozurdex is associated with significant mean improvement in visual acuity. A multimodality approach to treating DME is recommended, and clinicians should be informed of Ozurdex as a treatment option in patients who have a suboptimal response to anti-VEGF therapy.

Callanan et al. (2017) in a multicenter, open-label, 12-month, randomized, parallel-group, noninferiority study in 363 patients with DME, compared a 0.7 mg dexamethasone intravitreal implant with an anti-VEGF agent (ranibizumab). The study assessed whether dexamethasone delivered a mean change from baseline in BCVA every 5 months similar to ranibizumab 0.5 mg. At baseline, 5, and 10 months, patients received the dexamethasone implant, and ranibizumab was administered every 4 weeks until maximum visual acuity was obtained and remained constant over 3 visits. Treatment can then be discontinued but can be resumed if the BCVA decreases. The mean average improvement in BCVA was 4.34 letters in the dexamethasone group and 7.60 letters in the ranibizumab group over a one-year period. In patients with DME, both the dexamethasone implant and ranibizumab were well tolerated and improved BCVA. The dexamethasone implant was found to be noninferior to ranibizumab based on these findings; nevertheless, the dexamethasone group had a greater risk of IOP rise. Because of the occurrence of IOP increases and cataracts, ocular adverse events in the study eyes were more common in the dexamethasone implant group. IOP elevations were transient and were generally treated with topical medication. Cataract surgery was performed on 7 dexamethasone group patients and 1 ranibizumab group patient.

The Diabetic Retinopathy Clinical Research Network (DRCR Retina Network) conducted Protocol U, a phase 2, multicenter RCT evaluating a combination of dexamethasone implant (Ozurdex) and ranibizumab (Lucentis) versus ranibizumab monotherapy for the treatment of persistent DME. The study included 236 eyes with persistent DME despite receiving at least 3 anti-VEGF injections within 20 weeks of study enrollment. Patients were entered into a run-in phase to ensure that enrolled eyes truly had persistent DME. Among the 129 eyes, 65 eyes underwent combination treatment and 64 had ranibizumab alone. Retreatment with ranibizumab occurred as often as every 4 weeks if the Snellen equivalent was 20/25 or worse or if there was persistent edema. The combination arm was eligible for a second dexamethasone implant beginning at 3rd month and patients were followed to week 24. At 24 weeks, the authors found that there was no significant difference in visual acuity between the two treatment arms (Lucentis alone vs. Lucentis + dexamethasone implant). Both groups improved by approximately three additional letters over the study's 24-week phase. At 24 weeks, the addition of a dexamethasone implant had no effect on visual acuity compared to ongoing ranibizumab therapy alone. Although the combination therapy with dexamethasone implant resulted in a considerable improvement in macular thickness, this benefit was accompanied by a high incidence of IOP elevation.

National and Specialty Organizations**American Academy of Ophthalmology (AAO)**

The AAO published its Preferred Practice Pattern (PPP) for retinal vein occlusions in 2019: 'Macular edema may complicate both CRVOs and BRVOs. The first line of treatment for associated macular edema is anti-VEGFs. Intravitreal corticosteroids, with the associated risk of glaucoma and cataract formation, have demonstrated efficacy. Also, laser photocoagulation surgery in BRVO has a potential role in treatment.'

National Institute for Health and Clinical Excellence (NICE)***Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Secondary to RVO (2011; TA229)***

NICE published guidance on the use of the dexamethasone intravitreal implant for macular edema secondary to retinal vein occlusion. The dexamethasone implant is recommended as an option for the treatment of macular edema following CRVO. It is recommended as an option for the treatment of macular edema following BRVO when treatment with laser photocoagulation has not been beneficial, or if laser photocoagulation is not considered suitable because of the extent of macular hemorrhage.

Dexamethasone Intravitreal Implant for Treating DME (2015; TA349)

NICE provided guidance on the dexamethasone intravitreal implant (Ozurdex) for treating DME in 2015.

Molina Clinical Policy

Ozurdex (dexamethasone intravitreal implant): Policy No. 282

Last Approval: 6/8/2022

Next Review Due By: June 2023



Dexamethasone intravitreal implant is recommended as an option for treating DME in the following case:

- The implant is to be used in an eye with an intraocular pseudophakic (artificial) lens **and**
- DME does not respond to non-corticosteroid treatment, or such treatment is unsuitable

Adalimumab and Dexamethasone for Treating Noninfectious Uveitis (2017; TA460)

NICE released guidance in 2017 addressing the use of dexamethasone intravitreal implant (with adalimumab) for the treatment of noninfectious uveitis. NICE recommended the dexamethasone intravitreal implant is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is:

- Active disease (that is, current inflammation in the eye) and
- Worsening vision with a risk of blindness

SUPPLEMENTAL INFORMATION

N/A

CODING & BILLING INFORMATION

CPT	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure)

HCPCS	Description
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg [Ozurdex]

AVAILABLE DOSAGE FORMS: Biodegradable intravitreal implant containing dexamethasone 0.7 mg. *Ozurdex employs the Novadur™ solid polymer drug delivery system. Each implant comes preloaded in a specially designed, single-use applicator. The implant provides intravitreal dexamethasone for up to 6 months.*

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

6/8/2022 MCPC	Policy reviewed and updated. No changes in coverage criteria Updated references.
6/9/2021 MCPC	Policy revised. Updated references. IRO Peer Review. 5/19/2021. Practicing Physician. Board certified in Ophthalmology. Content update includes: In the 'Initial Coverage Criteria' section: <ul style="list-style-type: none">• DME and Non-infectious Posterior Segment Uveitis: the requirement for 'Triamcinolone acetonide, intravitreal injection' was removed• Macular Edema due to BRVO and CRVO: In the criterion 'FOR CRVO ONLY (BRVO not required)'—previously 'Triamcinolone acetonide, intravitreal injection' replaced with 'Intravitreal glucocorticoids' AND removed: 'Laser Photocoagulation [AS APPLICABLE ONLY]' requirement• Added criterion to #5: 'Member has been informed about the potential adverse effects of a corticosteroid intravitreal implant, including cataracts, increased intraocular pressure, or hypotony, endophthalmitis, and risk of need for additional surgical procedures'• Added criterion to #6 for congruency with existing continuation of treatment requirement: 'Prescriber to maintain record of administration of intravitreal therapy (recorded in the procedure or post-procedure note following the completion of treatments) with the following information: name of the medication, dose/amount of drug administered, and treated eye (right eye, left eye, or both eyes). Submit with re-authorization requests.'• Reauthorization/Continuation of Treatment section: Removed 'Member continues to meet initial coverage criteria' from criteria #1
Q3 2020 P&T	Policy reviewed and updated, no changes in coverage criteria, updated references.
Q3 2019 P&T	Policy revised. Updated references. IRO Peer Review. 7/10/2019. Practicing Physician. Board certified in Ophthalmology. Content update includes: Revised authorization limit criterion from ONE dexamethasone intravitreal implant per affected eye 'every 6 months' to 'every 4 to 6 months'
12/15/2016 MCPC	New policy. IRO Peer Review. 10/20/2016. Practicing Physician. Board certified in Ophthalmology, Surgery Vitreoretina.

REFERENCES

Government Agency

- Centers for Medicare and Medicaid Services (CMS). Medicare coverage database: National coverage determination (NCD) (search: Ozurdex, dexamethasone intravitreal implant). There are no CMS NCDs for Ozurdex available (May 2022). Accessed from [CMS](#).

Prescribing Information and Drug Compendia

- Ozurdex (dexamethasone) [prescribing information]. Irvine, CA: Allergan Inc; May 2018.
- Clinical Pharmacology. Available from [ClinicalKey](#). Published 2022. Accessed April 2022. Registration and login required.
- Drug Facts and Comparisons. Facts and comparisons eAnswers. Available from Wolters Kluwer Health, Inc. Accessed May 2022. Registration and login required.
- DynaMed. Diabetic retinopathy (record no. T116611). Updated December 4, 2018. Accessed May 2022. Available from [DynaMed](#). Registration and login required.
- DynaMed. Posterior uveitis (record no. T326288). Updated November 30, 2018. Accessed May 2022. Available from [DynaMed](#). Registration and login required.

Peer Reviewed Publications

- Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393–401. Available from [PMC](#), [PubMed](#).
- Boyer DS, Yoon YH, et al.; Ozurdex MEAD study group: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct; 121(10): 1904–14.
- Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):463-473.
- Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473-2481.
- Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or Dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology. 2016 Jun; 123(6): 1399–401. Available [here](#). Accessed May 2021
- Ip M.S., et al., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study. Arch Ophthalmol. 2009 Sep;127(9):1203-4.
- Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. Ophthalmologica. Sep 2015; 234(1):40-54. PMID 26088793
- Khan Z, Kuriakose RK, et al. Efficacy of the intravitreal sustained-release Dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: Meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 1;48(2):160-166. PMID: 28195619. Available [here](#). Accessed May 2021.
- Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34:719–724. Available [here](#).
- Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON study group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5):545-53. doi: 10.1001/archophthalmol.2010.339.
- Pielen, N. Feltgen, C. Isserstedt, J. et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: A systematic review. PLoS One. 2013 Oct 25;8(10):e78538. Available [here](#). Accessed April 2020
- Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127:1115.
- Tan HY, Agarwal A, Lee CS, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol. 2016;10:1983-2020. Published 2016 Oct 13. doi:10.2147/OPHTH.S89341. Accessed: May 2021.
- Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the United States: A claims-based analysis. JAMA Ophthalmol 2016;134:1237-1245.

National and Specialty Organizations

- American Academy of Ophthalmology (AAO)
 - Retinal vein occlusions PPP 2019. Oct 2019. Available [here](#). Accessed May 2021.
 - Therapies for macular edema associated with branch retinal vein occlusion: A report by the American Academy of Ophthalmology. (2017). Ophthalmology, 124 (9), pp. 1412-1423. Available [here](#). Accessed May 2021.
 - Therapies for macular edema associated with central retinal vein occlusion: A report by the American Academy of Ophthalmology. Ophthalmology. 2015 Apr. 122 (4):769-78. Available [here](#). Accessed May 2021.
- American Diabetes Association (ADA)
 - Standards of medical care in diabetes -- 2015. Diabetes Care 2015 Jan;38 Suppl 1:S1-93. Available [here](#). Accessed April 2020.
 - Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: A position statement by the American Diabetes Association. Diabetic Care 2017;40:412-418.
- National Institute for Health and Clinical Excellence (NICE)
 - Dexamethasone intravitreal implant for the treatment of macular edema secondary to retinal vein occlusion. NICE technology appraisal guidance [TA229]. Published July 27, 2011. Available from [NICE](#). Accessed May 2021.
 - Dexamethasone intravitreal implant for treating diabetic macular edema [TA349]. Published July 22, 2015. Available from [NICE](#). Accessed May 2021.
 - Adalimumab and dexamethasone for treating non-infectious uveitis [TA460]. Published July 26, 2017. Available from [NICE](#). Accessed May 2021.

Other Peer Reviewed and National Organization Publications (used in the development of this policy)

1. UpToDate.
 - Fraser, CE et al. Diabetic retinopathy: Prevention and treatment (topic 1773, version 27.0). Updated April 23, 2020. Accessed May 2022. Registration and login required.
 - Han, DP et al. Retinal vein occlusion: Treatment (topic 15263, version 37.0). Updated November 16, 2021. Accessed May 2022. Registration and login required.
 - Han, DP et al. Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis (topic 15264, version 38.0). Updated December 1, 2021. Accessed May 2022. Registration and login required.
 - Rosenbaum, JT et al. Uveitis: Treatment (topic 5592, version 35.0). Updated November 23, 2021. Accessed May 2022. Registration and login required.
2. Daruich A, Matet A, et al. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res. 2018 Mar;63:20-68. doi: 10.1016/j.preteyeres.2017.10.006. PMID: 29126927. Accessed May 2022.
3. He Y, Ren X, Hu B, et al. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol. 2018;18(1):121. doi: 10.1186/s12886-018-0779-1.
4. Ji K, Zhang Q, Tian M, et al. Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis. Medicine (Baltimore). 2019;98(22):e15798. doi: 10.1097/MD.00000000000015798.
5. [DEFINITION] Early treatment diabetic retinopathy study research group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103:1796–1806, 1985.
6. [DEFINITION] Wu L, Fernandez-Loaiza P, Sauma J, et al. Classification of diabetic retinopathy and diabetic macular edema. World Journal of Diabetes. 2013;4(6):290-4.
7. [DEFINITION] Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Survey of Ophthalmology. 2009;54(1):1-32.

APPENDIX

Reserved for State specific information. Information includes, but is not limited to, State contract language, Medicaid criteria and other mandated criteria.